Introduction 27
The global increase of multi-drug resistant (MDR) bacteria, combined with the decreasing 28 number of novel and effective antibacterial agents being developed for the market, poses a 29 serious global threat to human health 1,2 . Urgency is required with respect to discovery and 30 antimicrobial discovery can be circumvented using sequence and functional based 48 metagenomics, which allow mining of whole microbiomes for novel bioactive compounds 49 13, 14 . 50
Here, we report the discovery and characterization of three AMPs (i.e. Lynronne-1, 51
Lynronne-2 and Lynronne-3) via functional metagenomic screening of a rumen bacterial 52 metagenomic library and in-silico sequence data analysis. These novel AMPs from the rumen 53 microbiome have the potential to treat MDR bacterial infections. 54 55 Results 56
Identification of antimicrobial peptides 57
A metagenomic library consisting of 8,448 fosmids from the plant-attached rumen 58 microbiome 15 was screened for antimicrobial activity by a combination of agar-based 59 functional screening, sequencing of positive clones and bioinformatic prediction of AMP 60 sequences. To test the antimicrobial activity of fosmid clones, lawns of pathogens including methicillin sensitive Staphylococcus aureus (MSSA) RN4220, Escherichia coli K12, 2b and Extended Data Fig. 3c, d ), suggesting a non-specific mode of action 23 . The efficacy 111 of Lynronne-1, 2 and 3 against S. aureus biofilm attachment and established biofilms at sub 112 and supra-MIC concentrations were tested. MRSA ATCC 33591 strain was used in this assay 113 as it was a better biofilm former in our hands than the other strains (results not shown). All 114 AMPs decreased biofilm attachment at 2x MIC concentrations ( Fig. 2c ) and Lynronne-2 was 115 effective even at 0.25x MIC (data not shown). Anti-biofilm activity against established 116 biofilms was observed with all peptides at ≥ 2x MIC concentrations (Fig. 2c) . 117 Importantly, Lynronne-1, 2 and 3 also showed little haemolytic activity against red 118 blood cells ( Fig. 2d) . Similarly, Lynronne-1, 2 and 3 were less cytotoxic to mammalian 119 HUVEC and HepG2 cells when compared to the positive control agent, Staurosporine, which 120 had 50% Growth Inhibition (GI 50 ), Total Growth Inhibition (TGI) and 50% Lethal 121
Concentration (LC 50 ) of 0.00047, 0.0047 and 0.014 µg/ml respectively. Lynronne-2 had no 122 cytotoxic activity against mammalian HUVEC and HepG2 cells at the highest concentration 123 tested (128 µg/ml) while Lynronne-3 had little cytotoxicity at concentration close to the MIC 124 with GI 50 , TGI and LC 50 of 24.4, 61.2 and >128 µg/ml respectively. Lynronne-1 on the other 125 hand, had low toxicity at concentrations above the MIC with GI 50, TGI and LC 50 of 45.9, 67.1 126 and 98.1 µg/ml respectively. Whereas Lynronne-1 and 3 were able to permeabilize MRSA 127 USA300 cell membrane, very little permeabilization activity was observed for Lynronne-2 128 even at >3 times its MIC concentration ( Fig. 3a and Extended Data Fig. 4a ), demonstrating 129 that although antimicrobial activity of Lynronne-1 and 3 is due to pore formation, mechanism 130 of action of Lynronne-2 may be different. In accordance with cytotoxicity results, Lynronne-131 are targeted by these peptides. The use of MRSA lipid extract demonstrated a higher insertion 136 ability of Lynronne-1 and 3 compared to Lynronne-2 ( Fig. 3b ) and is in agreement with 137 bacteria membrane permeabilization. The use of pure lipids demonstrated that Lynronne-1, 2 138 and 3 preferentially interact with lipids specific to bacteria, including 1-palmitoyl-2-oleoyl-139 sn-glycero-3-(phospho-rac-(1-glycerol)) (POPG), cardiolipin, lipoteichoic acid (LTA) or 140 phosphatidylethanolamine (POPE) (also present in the inner membrane leaflet of eukaryotes) 141 above lipids only present in eukaryotes, such as Palmitoyloleoylphosphatidylcholine (POPC) 142 ( Fig. 3c and Extended Data Fig. 4c, d ). This may explain the limited haemolytic and 143 cytotoxic activity against mammalian cells in spite of their antibacterial activity. 144
Interestingly, Lynronne-2 showed the highest affinity for LTA demonstrated by measurement 145 of the critical pressure of insertion of the peptides in the different lipids (Extended Data Fig.  146 4d), suggesting that this peptide could target other molecules containing teichoic acid 147 moieties, including cell wall teichoic acids (WTA) and may also explain its antimicrobial 148 activity in the absence of pore-formation in whole bacteria. Transmission electron 149 micrographs of cells treated with Lynronne-1, 2 and 3 (at 3x MICs for 1 h) reveal varying 150 changes in cell morphology and some cytoplasmic leakage ( Fig Given the promising in vitro activity of Lynronne-1, 2 and 3, we investigated their in vivo 158 therapeutic potential within a murine model of MRSA skin infection 24 . Topical 159 administrations of Lynronne-1 (2% w/v), in a group of mice with MRSA infected wounds (5 160 mice/group) once daily for three days was associated with a significant decrease (P < 0.01) in 161 the colony count relative to the control group treated with phosphate buffered saline (PBS, 162 pH 7.4) ( Fig. 5a ). However, this decrease was less than a 2-log reduction (≥99%) in colony 163 counts. No significant decreases in colony counts were observed in the animal groups treated 164 with Lynronne-2 (2% w/v) and Lynronne-3 (2% w/v). The reference, 2% mupirocin ointment 165 (Dermasafe ® Ointment) was associated with a significant reduction (>2-log reduction, and P 166 < 0.001) in bacterial counts, consistent with historical data 24 . Given this promising in vivo 167 result for Lynronne-1, we further tested its efficacy at a higher dose (10% w/v) in the wound 168 model. Lynronne-1 at 10% (w/v) was associated with a significant (99%) reduction in 169 bacterial density (≥2-log reduction, and P < 0.001) and comparable to mupirocin (2%) 170 treatment ( Fig. 5b ). These findings suggest that Lynronne-1 can effectively reduce the 171 bacterial load in MRSA infected wounds. 172
The efficacy of Lynronne-1, 2 and 3 were subsequently tested in a murine model of 173 MRSA deep thigh infection 25 . The maximum tolerable dose (MTD) of all three AMPs was 174 predetermined to be 10 mg/kg in vivo in mice. Test animals were inoculated intramuscularly 175 (IM) in the right thigh with 0.1 ml/thigh of S. aureus MRSA ATCC 33591 (inoculum size of 176 1.57 × 10 5 CFU/mouse) followed by treatment with Lynronne-1, 2 and 3 and the comparator 177 antibiotic, vancomycin. Intravenous (IV) administrations of Lynronne-1, 2 and 3 at 10 mg/kg 178 once or twice (2 h or 2 and 8 h post infection) were not associated with any significant 179 antimicrobial effects compared to the vehicle/control group (0.9% NaCl). Vancomycin 180 administered twice at 30 mg/kg IV) elicited a significant reduction (≥99%, 2-log reduction in 181 CFU/g and P < 0.001). However, vancomycin at 10 mg/kg IV (administered twice) only 182 elicited a significant reduction (P < 0.001) but not a 2-log reduction in colony counts 183 compared to the control group ( Fig. 5c ).
Upon testing for stability of peptides, we observed that Lynronne-1 rapidly degraded 185 in the presence of serum with only 48% and 15% of the parent peptide remaining after 2 h 186 and 6 h respectively. Lynronne-2 and 3 were relatively more stable with ≥ 60% and 42%, as 187 well as ≥ 88% and 34% after 2 h and 6 h respectively ( Fig. 3d ). A similar pattern was 188 observed when these peptides were treated with trypsin (Extended Data Fig. 5 ), a common 189 feature among peptides that are susceptible to degradation by peptidases 26 Using a combination of functional metagenomics and computational approaches, we were 200 able to show that the rumen microbiome is a promising resource for bio-prospecting novel 201 AMPs, and these three peptides (Lynronne 1, 2 and 3), identified in this study are potential 202 therapeutic candidates. 203
Lynronne 1, 2 and 3 are efficacious against clinically important drug-resistant 204 pathogens in in vitro models of infection. In addition, Lynronne-1 decreased bacterial counts 205 in MRSA wound infections using a murine model similar to commercially used mupirocin 206 ointment, suggesting that it could be used topically in the treatment of MDR bacterial 207 infections. Lynronne 1, 2 and 3 displayed low haemolytic activity against blood cells and 208 negligible cytotoxicity against mammalian cells. Results presented here suggest that loss of 209 cell viability after exposure to Lynronne-1, 2 and 3 among many factors, is due to membrane 210 permeabilization, which contributes to membrane disruption and leakage of cell content. In 211 addition to their broad antibacterial spectrum, selectivity and rapid killing of bacterial cells, 212
Lynronne-1, 2 and 3 also showed a low tendency to select for resistance in the bacteria strains 213 tested. The antimicrobial compounds discovered here are novel and demonstrate potent 214 activity against clinically relevant human pathogens, rendering them as potential therapeutics. 215
The identification of these novels AMPs support the hypothesis that the rumen is a promising 216 resource for the discovery of novel antimicrobials with clinical relevance. 217
Online Methods 218

Functional antimicrobial activity screening of a rumen metagenomic library 219
A metagenomic library consisting of 8,448 clones from a plant-associated rumen microbiome 220 was prepared previously 15 To evaluate if populations of AMP-resistant bacteria could be selected, cultures were 282 continuously exposed to Lynronne-1, 2 and 3 for a duration of 25 days, as previously 283 described 40 . Briefly, broth microdilution susceptibility testing was performed using a 284 standard doubling-dilution series of Lynronne-1, 2 and 3 concentrations on day 1. Following 285 incubation of the cultures for 24 h, and determination of the MIC, the well that contained the 286 highest concentration of AMPs permitting growth was diluted 1: 1000 in MHB and used to 287 provide the inoculum for the next MIC assay; this process was repeated daily for 25 days. 
Cytotoxicity of peptides 297
Cytotoxic activity of the identified peptides was determined using HUVEC and HEPG2 cells 298 as described previously 41, 42 . Three dose response parameters 50% Growth Inhibition (GI 50 ), 299
Total Growth Inhibition (TGI) and 50% Lethal Concentration (LC 50 ) were calculated for each 300 experimental agent and cellular tumor assay results are presented as the percent cell growth 301 or percent tube length of specific activity. Significant responses were defined when observed 302 cell growth was ≤ 50% and tube length was ≤ 70% using the proliferation and tube formation 303 assays respectively. Permeabilization of eukaryotic membrane by Lynronne-1, 2 and 3 was 304 also investigated using HepG2 cells as described previously 43 . 305
Membrane permeabilization and peptide-lipid interactions 307
Membrane permeabilsation was evaluated using propidium iodide assay as previously 308 explained 43 , with CTAB as positive control. Peptide-lipid interaction was measured using 309 reconstituted lipid monolayer 44 The stability of Lynronne-1, 2 and 3 in the presence of serum was investigated by monitoring 336 the concentrations of the remaining soluble peptides by reverse phase high performance 337 liquid chromatography (RP-HPLC), as described previously by Nguyen and colleagues 26 . 338
Degradation of Lynronne-1, 2 and 3 in the presence of trypsin was adapted from a previously 339 described method 46 . Briefly, trypsin (5 µl of 0.5 ng/ml) and 37.5 µl trypsin activation buffer 340 (50 mM Tris, 2 mM CaCl 2 , pH 7.8-8) was added to 7.5 µl of 5 mg/ml Lynronne-1, 2 and 3 341 and incubated at 37 °C for different time points (0, 1, 3, and 24 h). An aliquot from each 342 reaction mixture at 0 h was prepared to allow matrix-assisted laser desorption/ionization 
Quantification of anti-biofilm activity 367
The effectiveness of Lynronne-1, 2, and 3 to prevent a) biofilm attachment and b) disrupt 368 established biofilms was measured using a 96 well biofilm model 50 . Briefly, MRSA cultures 369 grown in Brain Heart Infusion (BHI) broth were washed, resuspended to an OD 600nm = 0.02 in 370 BHI broth and a) treated with peptides (at 1/4x, 1/2x, 1x, 2x and 4x MIC) and incubated at 371 37 °C for 24 hours or b) incubated at 37 °C for 24 h to allow establishment of biofilms, 372 washed in PBS to remove planktonic cells, and further incubated with peptides (at 1/4x, 1/2x, 373 1x, 2x and 4x MIC) in fresh BHI broth at 37°C for 24 h. The biofilms were washed in PBS 374 to remove planktonic cells, fixed with methanol, stained with 0.5% (w/v) crystal violet and 375 re-solubilized with 33% (v/v) acetic acid. The optical density of biofilms was measured at 376 570 nm . 377 378
In vivo efficacy of peptides in a mouse model of MRSA skin and thigh infections 379
The efficacy of Lynronne-1, 2 and 3 for treating a wound infection caused by USA300 380 community-associated methicillin resistant S. aureus (MRSA, strain BAA-1717) was evaluated using a murine wound model with ICR mice 24 . A sharp punch (ID 12 mm) was 382 used to create excisional skin wounds in groups of five female ICR mice (5-6 weeks old). 383
The mice were inoculated topically on the wound area (5 µl per wound) with 1.05 × 10 5 384 CFU/mouse of strain BAA-1717 suspended in 5 µl PBS. Peptides (2% or 10% w/v) in PBS 385 (pH 7.4), control (PBS), and mupirocin 2% (Dermasafe ® ointment) were topically applied (20 386 µl/mouse) directly to wounds 2 h post infection and once daily thereafter for 3 consecutive 387 days. Test animals were sacrificed and the wound tissue was excised for enumeration of 388 bacteria cells (CFU/wound). A two-log reduction in the bacterial count (≥99% reduction) 389 relative to the control group indicates significant activity. Statistical significance (P < 0.05) 390 was performed with one-way ANOVA followed by use of the Dunnett's method. 391
In the thigh infection model, using neutropenic mice 25 , groups of five male ICR mice 392 weighing 22 ± 2 g were inoculated (1.57 × 10 5 CFU/mouse (0.1 ml/thigh)) intramuscularly 393 (IM) with S. aureus (MRSA, ATCC 33591) in the right thigh. Lynronne-1, 2 and 3 at 10 394 mg/kg were intravenously (IV) administered once 2 h post-infection or twice 2 and 8 h post-395 infection. The reference substance, vancomycin, was also intravenously injected 2 and 8 h 396 post-infection at 10 and 30 mg/kg. Test animals were sacrificed 26 h after inoculation and the 397 infected thighs were excised and the bacterial burden (CFU/gram) was determined. 398 399
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